Get the Stockscreener App
4.61
3.60%
0.16
After Hours:
4.61
Trisalus Life Sciences Inc stock is traded at $4.61, with a volume of 77,568.
It is up +3.60% in the last 24 hours and up +8.73% over the past month.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
See More
Previous Close:
$4.45
Open:
$4.48
24h Volume:
77,568
Relative Volume:
0.44
Market Cap:
$283.12M
Revenue:
$45.15M
Net Income/Loss:
$-39.23M
P/E Ratio:
-2.5205
EPS:
-1.829
Net Cash Flow:
$-18.93M
1W Performance:
+2.67%
1M Performance:
+8.73%
6M Performance:
+3.60%
1Y Performance:
-9.96%
1-Day Range:
$4.48
$4.64
1-Week Range:
$4.25
$4.64
52-Week Range:
$3.42
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.61 | 273.29M | 45.15M | -39.23M | -18.93M | -1.829 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Lake Street | Buy |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
View All
Trisalus Life Sciences Inc Stock (TLSI) Latest News
TriSalus initiates PREDICTT trial for liver tumor treatment - Investing.com
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors - Weekly Voice
Can pressure improve liver tumor treatment? TriSalus opens study at MD Anderson - Stock Titan
The stress test results at TriSalus (TLSIW) | TLSIW Latest Quarter Earnings: TriSalus has no EPS or revenue data this quarterIntrinsic Value - Newser
Tangible book value per share of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW - TradingView
Tristar Acquisition I Corp (TRIS) - Minichart
TLSI Stock Price, Quote & Chart | TRISALUS LIFE SCIENCES INC (NASDAQ:TLSI) - ChartMill
TriSalus Life Sciences Announces Planned Clinical Leadership Transition - TipRanks
TriSalus Life Sciences (NASDAQ: TLSI) outlines key leadership transitions - Stock Titan
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
Quarterly results arrive before TriSalus' May 12 webcast - Stock Titan
JonesTrading Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Thought-leader group to discuss work-life balance - BizWest
TriSalus (TLSI) Stock: Buy Decision Analysis (Breakdown Watch) 2026-04-20Most Discussed Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Frankenius Equity swaps preferred for 759,000 TriSalus (TLSI) common shares - Stock Titan
TriSalus Life Sciences (NASDAQ:TLSI) Trading Up 2%Time to Buy? - MarketBeat
Bull Run: Will TriSalus Life Sciences Inc benefit from rate cuts2026 Retail & Weekly Hot Stock Watchlists - baoquankhu1.vn
Sentiment Recap: Is TriSalus Life Sciences Inc Equity Warrant a strong growth stock2026 Earnings Impact & Consistent Profit Alerts - baoquankhu1.vn
TLSI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volume Summary: Is TriSalus Life Sciences Inc Equity Warrants growth already priced in2026 Price Swings & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Aug Swings: Is TriSalus Life Sciences Inc stock a value trap2026 Risk Factors & Reliable Price Breakout Signals - baoquankhu1.vn
TriSalus Life Sciences to Present New Data at 2026 Radiology Conference - National Today
TriSalus to present drug delivery data at radiology meeting By Investing.com - Investing.com South Africa
TriSalus to present drug delivery data at radiology meeting - Investing.com
TriSalus brings liver and uterine treatment data to SIR 2026 - Stock Titan
TriSalus to elevate director to chief medical officer role - BizWest
Trisalus Life Sciences, Inc. Appoints Richard Marshall, M.D., as Chief Medical Officer, Effective June 29, 2026 - marketscreener.com
TriSalus names Richard Marshall as chief medical officer By Investing.com - Investing.com India
TriSalus Life Sciences, Inc. Files Form 8-K on April 1, 2026 Announcing Press Release and Company Information - Minichart
TriSalus names Richard Marshall as chief medical officer - Investing.com
TriSalus Life Sciences Names Richard Marshall Chief Medical Officer - TipRanks
Transcend Appoints Elizabeth Jackson as Senior Vice President of Marketing - Weekly Voice
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer - Weekly Voice
Oncology company TriSalus taps interventional radiologist as medical chief - Stock Titan
TriSalus Life Sciences (TLSI) taps Richard Marshall, M.D., as Chief Medical Officer - Stock Titan
Will TriSalus (TLSI) Stock Rise in 2026 | Price at $4.11, Down 3.07%High Yield Stocks - Cổng thông tin điện tử Tỉnh Sơn La
TLSI Technical Analysis & Stock Price Forecast - Intellectia AI
Laramie’s Unlocked Labs fights kidney stones with enzymes - BizWest
How does currency impact TriSalus (TLSI) Stock | Price at $4.24, Up 1.44%Social Buy Zones - Newser
Director converts 100,000 TriSalus (TLSI) preferred shares into common - Stock Titan
TLSI Should I Buy - Intellectia AI
Revenue Check: Why is TriSalus Life Sciences Inc stock going up2026 Key Highlights & Entry Point Confirmation Signals - baoquankhu1.vn
Aug PreEarnings: Is TriSalus Life Sciences Inc Equity Warrant in a long term uptrend2026 Market Mood & Technical Buy Zone Confirmation - baoquankhu1.vn
Executive pay and board elections at TriSalus (TLSI) 2026 virtual shareholder meeting - Stock Titan
Aug PreEarnings: Is TriSalus Life Sciences Inc Equity Warrants growth already priced inDip Buying & Weekly Top Performers Watchlists - baoquankhu1.vn
Published on: 2026-03-26 07:22:01 - baoquankhu1.vn
Momentum Shift: Does TriSalus Life Sciences Inc have pricing power2026 Top Gainers & Technical Confirmation Alerts - baoquankhu1.vn
What is Northland Securities' Estimate for TLSI Q1 Earnings? - MarketBeat
TLSI SEC FilingsTriSalus Life Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $17,998.54 in Stock - Defense World
Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $61,384.40 in Stock - Defense World
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):